Abstract
The last three decades have seen major advances in the pharmacological treatment of patients with heart failure. ACE inhibitors, beta blockers, Spironolactone and ARB’s have all been shown to improve symptoms, and prolong life, by a reduction in the risk of sudden cardiac death (SCD) and the risk of death due to progressive heart failure. These treatments constitute what is termed optimal medical treatment. Nevertheless, despite optimal medical treatment patients with heart failure remain at increased risk of SCD and death due to progressive heart failure. In addition, many patients remain symptomatic in NYHA Classes II, III or even IV.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
The antiarrhythmics versus implantable defibrillators (AVID) investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576-1583.
Kuck KH, Cappato R, Siebels J, Rüppel R. Defibrillators in patients resuscitated from cardiac arrest: The Cardiac Randomized Comparison of Antiarrhythmic Drug Therapy With Implantable Arrest Study Hamburg (CASH). Circulation. 2000;102:748-754.
Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-1302.
Connolly AP, Hallstrom R, Cappato EB, et al.; on behalf of the investigators of the AVID, CASH and CIDS studies. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J. 2000;21:2071-2078.
Owen A. How should the efficacy of novel treatments be assessed in survival trials? Int J Cardiol. 2007;120:297-300.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statist Med. 2002;21:1539-1558.
Daubert JP, Zareba DS, Cannom DS, et al.; for the MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51:1357-1365.
Mark DB, Anstrom KJ, Sun JL, et al.; for the Sudden Cardiac Death in Heart Failure Trial Investigators. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med. 2008;359:999-1008.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:2820-2840.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur Heart J. 2008:29;2388-2442.
Moss AJ, Zareba W, Jackson Hall W, et al.; for the multicentre automatic defibrillator implantation trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
Wilber DJ, Zareba W, Hall J, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation. 2004;109:1082-1084.
Kadish A, Dyer A, Daubert JP, et al.; for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158.
Bardy GH, Kerry LL, Daniel BM, et al.; for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
Hohnloser SH, Kuck KH, Dorian P, et al.; on behalf of the DINAMIT Investigators. Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-4288.
Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292(23):2874-2879.
Bristow MR, Saxon LA, Boehmer, J et al.; for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an Implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
Strickberger SA, Hummel JD, Bartlett MC, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia – AMIOVIRT. J Am Coll Cardiol. 2003;41:1707-1712.
Poole JE, Johnson GW, Hellhamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009-1017.
Køber L, Torp-Pedersen C, McMurray JJV, et al.; for the Dronedarone Study Group. Increased mortality after dromedaries. Therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687.
Cazeau S, Leclercq C, Lavergne T, et al.; for the multisite stimulation in cardiomyopathies (MUSTIC) study investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873-880.
Auricchio A, Stellbrink C, Sack S, et al.; for the Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol. 2002;39:2026-2033.
Abraham WT, Fisher WG, Smith AL, et al.; for the MIRACLE study group. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
Cleland JGF, Daubert J-C, Erdmann E, et al.; for the Cardiac Resynchronization – Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549.
Cleland JGF, Daubert J-C, Erdmann E, et al.; on behalf of the CARE-HF Study Investigators. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure (the Cardiac REsynchronization-Heart Failure (CARE-HF) trial extension phase). Eur Heart J. 2006;27:1928-1932.
Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA. 2003;289(20):2685-2694.
Higgins SL, Hummel JD, Imran K, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:1454-1459.
Abraham WT, Young JB, Leon AR, et al.; on behalf of the Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864-2868.
Lam S, Owen A. Combined resynchronization and defibrillation therapy in left ventricular dysfunction: bayesian network meta-analysis of randomized controlled trials. BMJ. 2007;335:925-934.
Maisch B, Soler-Soler J, Hatle L, et al. The ESC Textbook of Cardiovascular Medicine. In: Camm AJ, Luscher TF, Serruys PW, eds. Oxford: Blackwell Publishing; 2006.
Chung ES, Leon AR, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608-2616.
Henein MY, Amadia A, O’Sullivan C, Coats A, Gibson D. ACE inhibitors unmask incoordinate diastolic wall motion in restrictive left ventricular disease. Heart. 1996;76:326-331.
Owen A, Cox S. Diagnosis of heart failure in elderly patients in primary care. Eur J Heart Failure. 2001;3:79-81.
Rathore SS, Yongfeiwang MPH, Krumholz HR. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403-1411.
Hsu L-F, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373-2383.
The DAVID Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the dual chamber and vvi implantable defibrillator (david) trial. JAMA. 2002;288(24):3115-3123.
Cleland JGF, Daubert JC, Erdmann E, et al.; on behalf of the CARE-HF study Steering Committee and Investigators. The CARE-HF study CArdiac REsynchronisation in Heart Failure study/rationale, design and end-points. Eur J Heart Failure. 2001;3:481-489.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer London
About this chapter
Cite this chapter
Owen, A. (2010). Device Therapy in Heart Failure. In: Henein, M. (eds) Heart Failure in Clinical Practice. Springer, London. https://doi.org/10.1007/978-1-84996-153-0_19
Download citation
DOI: https://doi.org/10.1007/978-1-84996-153-0_19
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84996-152-3
Online ISBN: 978-1-84996-153-0
eBook Packages: MedicineMedicine (R0)